Evidence map›Paper›PMID 41832156›Full record

ArticleNature communications2026

Control of lysosome function by the GTPase-activating protein TBC1D9B and its binding partner TMEM55B.

Valentin Duhay, Miaomiao Tian, Klaudia Kosieradzka, Michael Ebner, Wen-Ting Lo, Michael Krauss, Henner-Linus Sprengel, Matthias Voss, Mara Riechmann, Jeffrey N Savas and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valentin Duhay *Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.ORCID 0009-0009-6033-9210
Miaomiao Tian *Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.ORCID 0009-0008-7264-9999
Klaudia KosieradzkaLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.ORCID 0009-0002-1171-7579
Michael EbnerLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.ORCID 0000-0003-4234-7187
Wen-Ting LoGraduate Institute of Biochemistry, College of Life Sciences, National Chung Hsing University, Taichung City, Taiwan.ORCID 0000-0001-7904-6834
Michael KraussLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.ORCID 0000-0003-1010-9723
Henner-Linus SprengelInstitute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.
Matthias VossInstitute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.ORCID 0000-0002-4217-3175
Mara RiechmannInstitute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.ORCID 0000-0002-4611-5351
Jeffrey N SavasKen and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0002-8173-5580
Michael SchwakeBiochemistry III/Faculty of Chemistry, Bielefeld University, Bielefeld, Germany.ORCID 0000-0002-4173-2166
Volker HauckeLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany. haucke@fmp-berlin.de.ORCID 0000-0003-3119-6993
Markus DammeInstitute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany. markus.damme@uni-bielefeld.de.ORCID 0000-0002-9699-9351

Funding

Understanding Amyloid Pathology - Multiomic Activity Imaging of Plaque Formation Dynamics (AmyMAP)R01AG078796 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Jeffrey Nicholas Savas · 2022 to 2026
$2.7M
Orbitrap Eclipse Mass Spectrometer for Northwestern University Neuroproteomic Collaboration HubS10OD032464 · OD · NORTHWESTERN UNIVERSITY · PI SAVAS, JEFFREY NICHOLAS · 2023 to 2023
$1.3M
Deutsche Forschungsgemeinschaft (German Research Foundation) DA 1785/2-2Deutsche Forschungsgemeinschaft (German Research Foundation) HA2686/26-1Deutsche Forschungsgemeinschaft (German Research Foundation) SCHW866/6-1Deutsche Forschungsgemeinschaft (German Research Foundation) SCHW866/7-1Deutsche Forschungsgemeinschaft (German Research Foundation) TRR186/A08NIA NIH HHS R01 AG078796NIH HHS S10 OD032464
6 · The paper itself

Abstract

Lysosomes are highly dynamic organelles that serve antagonistic functions as terminal catabolic stations for the degradation of macromolecules and as central metabolic decision centers for anabolic growth signaling. Lysosome dysfunction is implicated in various human diseases. The physiological roles of lysosomes are linked to the control of lysosome position and dynamics via the activity of the kinesin-activating small GTPase ARL8. How the activity of ARL8 is regulated remains poorly understood. Here, we identify the GTPase-activating Tre-2/Bub2/Cdc16 (TBC) domain protein TBC1D9B as a critical negative regulator of ARL8B function. We demonstrate that TBC1D9B is associated with the lysosomal membrane protein TMEM55B, directly binds to ARL8B-GTP, and stimulates its GTPase activity. Knockout of TBC1D9B or its binding partner TMEM55B causes lysosome dispersion, defective autophagic flux, and impairs the adaptive degradative response of cells to limiting nutrient supply. These lysosomal phenotypes of TBC1D9B loss are occluded by concomitant depletion of ARL8 in cells. Collectively, our data unravel a key role for TBC1D9B in controlling lysosome function by serving as a negative regulator of ARL8 activity.

Indexed as

ADP-Ribosylation FactorsGTPase-Activating ProteinsLysosomesMembrane ProteinsAnimalsAutophagyHEK293 CellsHeLa CellsHumansProtein BindingADP-Ribosylation FactorsARL8B protein, humanGTPase-Activating ProteinsMembrane Proteins

Identifiers

PMID41832156
PMCPMC12992710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.